MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

15.05 +0.06 (+0.40%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist

Price and Volume

Volume	1,017,675
Open	14.94
Bid (Size)	14.80 (100)
Ask (Size)	15.18 (1,000)
Prev. Close	14.99
Today's Range	14.63 - 15.11
52wk Range	5.950 - 62.75
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MoonLake Immunotherapeutics' CFO Sells 39K Shares ↗

July 03, 2026

This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.

Via The Motley Fool

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday ↗

June 24, 2026

The biotech is floating a relatively sizable secondary share issue.

Via The Motley Fool

Performance

YTD	+25.9%	+25.9%
1 Month	-18.4%	-18.4%
3 Month	-20.0%	-20.0%
6 Month	-14.9%	-14.9%
1 Year	-74.3%	-74.3%

More News

MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? ↗

June 04, 2026

Via The Motley Fool

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗

January 09, 2026

Via Stocktwits

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? ↗

April 18, 2026

Via The Motley Fool

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares ↗

April 07, 2026

Via The Motley Fool

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

Via The Motley Fool

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Via The Motley Fool

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Via Stocktwits

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗

February 22, 2026

Via Stocktwits

MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗

February 19, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗

February 18, 2026

Via Stocktwits

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗

February 17, 2026

Via Stocktwits

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

February 10, 2026

From ImageneBio, Inc.

Via GlobeNewswire

BioTech Breakout: MoonLake Up 30% On FDA Wins ↗

February 03, 2026

Via MarketBeat

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗

January 15, 2026

Via Stocktwits

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

Via MarketMinute

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗

January 08, 2026

Via Stocktwits

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

December 15, 2025

From DJS Law Group

Via Business Wire

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?

Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.

What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?

MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?

The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market

What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?

The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 15.05

When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?

The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 08/31/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.